Compare LOB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | NVCR |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2014 | 2015 |
| Metric | LOB | NVCR |
|---|---|---|
| Price | $40.76 | $15.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $43.00 | $28.08 |
| AVG Volume (30 Days) | 253.8K | ★ 1.5M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | 21.79 |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $35.52 | $7.72 |
| Revenue Next Year | $16.03 | $6.74 |
| P/E Ratio | $68.27 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $29.36 | $9.82 |
| 52 Week High | $42.89 | $18.92 |
| Indicator | LOB | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 44.32 |
| Support Level | $39.43 | $14.85 |
| Resistance Level | $42.72 | $15.19 |
| Average True Range (ATR) | 0.99 | 0.87 |
| MACD | 0.25 | -0.33 |
| Stochastic Oscillator | 85.08 | 34.48 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.